News Releases

January 15, 2021
Taiho Pharmaceutical Co., Ltd.

Taiho Pharmaceutical Announces Establishment of a New Company as a Clinical Development and Commercial Base in Switzerland

Taiho Pharmaceutical Co., Ltd. announced its establishment of a new headquarters, Taiho Oncology Europe GmbH in Zug, Switzerland, as a clinical development and commercial base for its pharmaceutical business in Europe.

Taiho Oncology Europe is established as a subsidiary of Taiho Pharmaceutical. Together with Taiho Pharmaceutical, Taiho Oncology, Inc. (Princeton, New Jersey), a subsidiary of Taiho Pharmaceutical, will support its operation in Europe.

Taiho Oncology Europe will be responsible for the European commercialization of futibatinib (development code; TAS-120), an FGFR inhibitor currently under development as a new oral anti-cancer agent, after obtaining marketing approval. Futibatinib is not yet approved in any country worldwide.

Taiho Pharmaceutical will further promote its globalization through Taiho Oncology Europe, and will strive to continue its contribution to cancer patients and caregivers worldwide.

Taiho Oncology Europe GmbH Overview

Company Name

Taiho Oncology Europe GmbH

Established

January 8th, 2021

Manager

Atsushi Azuma (Chairman)

Location

Zug, Switzerland

Capital

2,000,000 Swiss Francs

Ownership ratio

100% Taiho Pharmaceutical

Business

Clinical Development and Commercialization of Pharmaceuticals

About Taiho Pharmaceutical Co., Ltd. (Japan)

Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd., is an R&D-driven specialty pharma company with a focus on oncology. Taiho Pharmaceutical also has development programs in allergy and immunology, urology and consumer healthcare products. Our corporate philosophy is simple: “We strive to improve human health and contribute to a society enriched by smiles.” For more information about Taiho Pharmaceutical Co., Ltd., please visit:

https://www.taiho.co.jp/en/

About Taiho Oncology, Inc. (U.S.)

Taiho Oncology, Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. and Otsuka Holdings Co., Ltd., has established a world class clinical development organization that works urgently to develop innovative cancer treatments and has built a commercial business in the U.S. Taiho Oncology has an oral oncology pipeline consisting of selectively targeted agents. Advanced technology, dedicated researchers, and state of the art facilities are helping us to define the way the world treats cancer. It’s our work; it’s our passion; it’s our legacy. For more information about Taiho Oncology, please visit:

https://www.taihooncology.com/us

Information in this news release was current as of the original release date.

  • TOP
  • News Releases
  • 2021
  • Taiho Pharmaceutical Announces Establishment of a New Company as a Clinical Development and Commercial Base in Switzerland